Adjuvant aromatase inhibitor therapy: Outcomes and safety

Cancer Treatment Reviews

Volumn 36, Issue 3, 2010, Pages 249-261

  Janni, Wolfgang ^a   Hepp, Philip ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Adjuvant therapy; Adverse events; Anastrozole; Aromatase inhibitor; Exemestane; Letrozole; Safety; Tamoxifen

Indexed keywords

ANALGESIC AGENT; ANASTROZOLE; AROMATASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLONIDINE; COLECALCIFEROL; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; EXEMESTANE; GABAPENTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; LETROZOLE; MEDROXYPROGESTERONE; MEGESTROL ACETATE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; RISEDRONIC ACID; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ALOPECIA; ANEMIA; ANGINA PECTORIS; ANOREXIA; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; ASTHENIA; ATHEROSCLEROSIS; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARPAL TUNNEL SYNDROME; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITION; DIARRHEA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPAREUNIA; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FRACTURE; GYNECOLOGIC DISEASE; HAIR LOSS; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSOMNIA; ISCHEMIC HEART DISEASE; LIBIDO DISORDER; MONOTHERAPY; MUSCLE CRAMP; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; MYALGIA; MYCOSIS; NAIL DISEASE; NAUSEA; NIGHT SWEAT; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; PARESTHESIA; POLYP; POSTMENOPAUSE; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UTERINE POLYP; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL DRYNESS; VAGINITIS; VISUAL DISORDER; VITAMIN SUPPLEMENTATION; WEIGHT GAIN; XEROSTOMIA;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; TREATMENT OUTCOME;

EID: 77951255371     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.12.010     Document Type: Review

References (116)

1. Thürlimann B., Keshaviah A., Coates A.S., et al. Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757.
2. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9:45-53. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group.
3. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369:559-570.
4. Jonat W., Hilpert F., Kaufmann M. Aromatase inhibitors: a safety comparison. Expert Opin Drug Saf 2007, 6:165-174.
5. Aiello E.J., Buist D.S., Wagner E.H., et al. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat 2008, 107:397-403.
6. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007, 25:486-492.
7. Mouridsen H., Giobbie-Hurder A., Goldhirsch A., et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009, 361:766-776.
8. Jones S.E., Seynaeve C., Hasenburg A., et al. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast. Cancer Res. 2009, 69:67s. [abstract 15].
9. Kaufmann M., Jonat W., Hilfrich J., et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 2007, 25:2664-2670.
10. Jakesz R., Gnant M., Greil R., et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG trial 8. Breast Cancer Res Treat 2005, 94(Suppl. 1):S10. [abstract 13].
11. Jakesz R., Gnant M., Greil R., et al. Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. Cancer Res 2009, 69(Suppl.):67s. [abstract 14].
12. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005, 97:1262-1271.
13. Jakesz R., Greil R., Gnant M., et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group trial 6a. J Natl Cancer Inst 2007, 99:1845-1853.
14. Mansell J., Monypenny I.J., Skene A.I., et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat 2009, 117:91-98.
15. Lamerato L., Havstad S., Gandhi S., Jones D., Chlebowski R. Breast cancer recurrence and related mortality in US pts with early breast cancer. J Clin Oncol 2005, 23(16S):62s. [abstract 738].
16. Howell A., Cuzick J., Baum M. Et al. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365:60-62.
17. Thürlimann B. For the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer: update of the BIG 1-98 primary core analysis (PCA). In: Primary therapy of early breast cancer 2009, 11th international conference, March 11-14, St. Gallen, Switzerland [abstract 0161].
18. Chapman J.A., Meng D., Shepherd L., et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 2008, 100:252-260.
19. Goss P.E., Ingle J.N., Pater J.L., et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008, 26:1948-1955.
20. Mackey J.R., Joy A.A. Skeletal health in postmenopausal survivors of early breast cancer. Int J Cancer 2005, 114:1010-1015.
21. International Osteoporosis Foundation. Osteoporosis in the European community: action plan. A report of the key next steps towards a Europe free from fragility fractures. November 2003. ; 2009 [accessed 23.07.09]. http://www.iofbonehealth.org/publications.html.
22. Rubin C.D. Emerging concepts in osteoporosis and bone strength. Curr Med Res Opin 2005, 21:1049-1056.
23. Buzdar A., Howell A., Cuzick J., et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006, 7:633-643. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group.
24. Shapiro C.L. Aromatase inhibitors and bone loss: risks in perspective. J Clin Oncol 2005, 23:4847-4849.
25. Goss P.E., Qi S., Cheung A.M., et al. Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res 2004, 10:5717-5723.
26. McCaig F.M., Renshaw L., Williams I., et al. A randomized study of the effects of anastrozole (A), letrozole (L) and exemestane (E) on bone turnover. Cancer Res. 2009, 69:148s. abstract 1145.
27. Hadji P., Ziller M., Kieback D., et al. Cancer Res. 2009, 69:148s. [abstract 1143].
28. Coleman R.E., Banks L.M., Girgis S.I., et al. Intergroup Exemestane Study group. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007, 8:119-127.
29. Jones S.E., Cantrell J., Vukelja S., et al. The effect of tamoxifen (T) or exemestane (E) on bone mineral density (BMD) after 1 year of adjuvant treatment of postmenopausal women with early breast cancer. J Clin Oncol 2005, 23(16S):31s. [abstract 610].
30. Geisler J., Lonning P.E., Krag L.E., et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer 2006, 42:2968-2975.
31. Pfeilschifter J., Diel I.J. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000, 18:1570-1593.
32. Perez E.A., Josse R.G., Pritchard K.I., et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006, 24:3629-3635.
33. Reginster J.Y. The high prevalence of inadequate serum vitamin D levels and implications for bone health. Curr Med Res Opin 2005, 21:579-586.
34. Lonning P., Geisler J., Krag L.E., et al. Vitamin D deficiency a threat to bone health in breast cancer patients during adjuvant treatment with aromatase inhibitors. J Clin Oncol 2006, 24(18S):16s. [abstract 554].
35. Lester J.E., Dodwell D., Purohit O.P., et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008, 14:6336-6342.
36. Van Poznak C., Hannon R.A., Clack G., et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study 12-month analysis. Breast Cancer Res Treat 2007, 106(1):S37. [abstract 502].
37. Brufsky A., Dong M., Lund K., et al. Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). Breast Cancer Res Treat 2006, 100(1):S233. [abstract 5060].
38. Brufsky A., Harker W.G., Beck J.T., et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007, 25:829-836.
39. Bundred N.J., Campbell I.D., Davidson N., et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008, 112:1001-1010.
40. Brufsky A., Bosserman L., Caradonna R., et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 36-month follow-up. Breast Cancer Res Treat 2007, 106(1):S8. [abstract 27].
41. Eidtmann H., Bundred N.J., DeBoer R., et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Cancer Res 2009, 69:74s. [abstract 44].
42. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005, 23:619-629.
43. Hadji P., Aapro M., Brufsky A., et al. Practical guidance for the prevention of aromatase inhibitor-associated bone loss in women with breast cancer. Ann Oncol 2008, 19:1407-1416.
44. Aapro M., Abrahamsson P.A., Body J.J., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008, 19:420-432.
45. Hadji P., Bundred N. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer. Semin Oncol 2007, 34(6 Suppl. 4):S4-S10.
46. Thorne C. Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol 2007, 14(Suppl. 1):S11-S19.
47. American Heart Association. Heart disease and stroke statistics-2009 update. Dallas, TX. American Heart Association. ; 2009 [accessed 23.07.09]. http://www.americanheart.org/downloadable/heart/1240250946756LS-1982%20H eart%20and%20Stroke%20Update.042009.pdf.
48. European Cardiovascular Disease Statistics. 2005 ed. ; 2009 [accessed 22.07.09]. http://www.ehnheart.org/files/statistics%202005-092711A.pdf.
49. Joensuu H., Ejlertsen B., Lonning P.E., Rutqvist L.E. Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncol 2005, 44:23-31.
50. Howell A., Cuzick J. Vascular effects of aromatase inhibitors: data from clinical trials. J Steroid Biochem Mol Biol 2005, 95(1-5):143-149. [Erratum in: J Steroid Biochem Mol Biol 2006;98(2-3):180].
51. Aromatase inhibitors in early breast cancer therapy. Semin Oncol 2004;31(6 Suppl. 12):9-14.
52. Herrington D.M., Klein K.P. Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues 2001, 11:95-102.
53. McCaig F.M., Renshaw L., Williams L., et al. A randomised study comparing the effects of anastrozole and letrozole on lipid metabolism. Cancer Res. 2009, 69:150s-151s. [abstract 1152].
54. McCloskey E.V., Hannon R.A., Lakner G., et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 2007, 43:2523-2531.
55. Perez E.A. The balance between risks and benefits: long-term use of aromatase inhibitors. Eur J Cancer Suppl 2006, 4:16-25.
56. Markopoulos C., Polychronis A., Dafni U., et al. Lipid changes in breast cancer patients on exemestane treatment: final results of the TEAM Greek substudy. Ann Oncol 2009, 20:49-55.
57. Hori Y., Akizuki M., Nishimura R. Comparison of adverse effects of lipid metabolism of anastrozole with tamoxifen in adjuvant setting for postmenopausal women with early breast cancer. Eur J Cancer Suppl 2006, 4:94. [abstract 172].
58. Wasan K.M., Goss P.E., Pritchard P.H., et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 2005, 16:707-715.
59. Markopoulos C., Chrissochou M., Michailidou A., et al. Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anticancer Drugs 2005, 16:879-883.
60. Arimidex® anastrozole tablets. Prescribing information. AstraZeneca Pharmaceuticals LP, December 2008.
61. Mouridsen H., Keshaviah A., Coates A.S., et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 2007, 25:5715-5722.
62. Bradbury B.D., Lash T.L., Kaye J.A., Jick S.S. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina. Cancer 2005, 103:1114-1121.
63. Nordenskjold B., Rosell J., Rutqvist L.E., et al. Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst 2005, 97:1609-1610.
64. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371-1388.
65. Fisher B., Dignam J., Bryant J., Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001, 93:684-690.
66. Geiger A.M., Chen W., Bernstein L. Myocardial infarction risk and tamoxifen therapy for breast cancer. Br J Cancer 2005, 92:1614-1620.
67. Braithwaite R.S., Chlebowski R.T., Lau J., George S., Hess R., Col N.F. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003, 18:937-947.
68. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
69. Cuppone F., Bria E., Verma S., et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 2008, 112:260-267.
70. Sourander L., Rajala T., Raiha I., Makinen J., Erkkola R., Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 1998, 352:1965-1969. [Erratum in: Lancet 1999;353:330].
71. Monnier A, Sakek N, Aladen S. Comparing AI cardiovascular safety data: trial comparators and outcomes. Ann Oncol 2006;17(Suppl. 9):ix100 [abstract 266P].
72. Medicines and Healthcare Products Regulatory Agency (MHRA). Publication assessment report Femara 2.5Mg tablet, 2006. ; 2009 [accessed 23.07.09]. http://www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/co n2023055.pdf.
73. Grundy S.M., Cleeman J.I., Merz C.N., et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004, 24:e149-e161.
74. Ewer M.S., Glück S. A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health. Cancer 2009, 115:1813-1826.
75. Donnellan P.P., Douglas S.L., Cameron D.A., et al. Aromatase inhibitors and arthralgias. J Clin Oncol 2001, 19:2767.
76. Mackey J., Gelmon K. Adjuvant aromatase inhibitors in breast cancer therapy: significance of musculoskeletal complications aromatase inhibitors and musculoskeletal complications. Curr Opin Oncol 2007, 10(1):S9-S18.
77. Garreau J.R., Delamelena T., Walts D., Karamlou K., Johnson N. Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective. Am J Surg 2006, 192:496-498.
78. Crew K.D., Greenlee H., Capodice J., et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007, 25:3877-3883.
79. Burstein H.J. Aromatase inhibitor-associated arthralgia syndrome. Breast 2007, 16:223-234.
80. Renshaw L., McHugh M., Williams L., et al. Comparison of joint problems as reported by patients in a randomised adjuvant trial of anastrozole and letrozole. Breast Cancer Res Treat 2007, 106(1):S108-S109. [abstract 2072].
81. Briot K., Bastit L., Rotarsky M., et al. Effects of switching aromatase inhibitors on arthralgia: the ATOLL study. Cancer Res 2009, 69(l):147s-148s. [abstract 1142].
82. Cuzick J., Sestak I., Cella D., Fallowfield L. ATAC Trialists' Group. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 2008, 9:1143-1148.
83. Arora A., Potter J.F. Aromatase inhibitors: current indications and future prospects for treatment of postmenopausal breast cancer. J Am Geriatr Soc 2004, 52:611-616.
84. Tralongo P., Dimari A., Repetto L. Aromatase inhibitors and mental function. J Am Geriatr Soc 2005, 53:166.
85. Schilder C.M., Schagen S.B. Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature. Minerva Ginecol 2007, 59:387-401.
86. Jenkins V., Shilling V., Fallowfield L., Howell A., Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 2004, 13:61-66.
87. Paganini-Hill A., Clark L.J. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2000, 64:165-176.
88. Schilder M, Eggens PC, Boogerd W, et al. Neuropsychological sequelae of tamoxifen and exemestane after AC-chemotherapy in postmenopausal women with early breast cancer. J Clin Oncol 2007;25(18S):56s [abstract 1099].
89. Schilder C.M., Seynaeve C., Linn S.C., et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with early breast cancer results from the TEAM trial neuropsychological side study. Cancer Res 2009, 69(Suppl.):144s-145s. [abstract 1133].
90. Schilder C.M., van Dam F., Boogerd W.S., et al. Prevalence of cognitive complaints is not higher in postmenopausal breast cancer patients before adjuvant hormonal therapy compared to healthy controls. Breast Cancer Res Treat 2007, 106(1):S76. [abstract 1099].
91. Asmar L., Cantrell J., Vukelja S.J., et al. Final analysis of a planned comparison of menopausal symptoms in 1618 patients receiving either exemestane (E) or tamoxifen (T) in a blinded adjuvant hormonal study. Breast Cancer Res Treat 2005, 95(1):S97. [abstract 2039].
92. Bender C.M., Sereika S.M., Brufsky A.M., et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 2007, 14:995-998.
93. Rugo H.S., Ahles T. The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Semin Oncol 2003, 30:749-762.
94. Duffy S., Jackson T.L., Lansdown M., et al. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006, 21:545-553.
95. Thomas RJ., Marshall CJ., Williams M., Walker L.G. Does switching to letrozole improve hot flushes mood and quality of life in tamoxifen intolerant patients?. Breast Cancer Res Treat 2005, 94(1):S107. [abstract 2067].
96. Aromasin® exemestane tablets. Prescribing Information. Pfizer, Inc., February 2007.
97. Whelan TJ, Pritchard KI. Managing patients on endocrine therapy: focus on quality-of-life issues. Clin Cancer Res 2006;12(3 Pt 2):1056s-60s.
98. Howard G., Wills S., Kresge C., McConnell D., Balasubramaniam M., Decker D. The effects of vaginal estrogens on plasma estradiol levels in women taking aromatase inhibitors. Breast Cancer Res Treat 2007, 106(1):S155. [abstract 3085].
99. Bygdeman M., Swahn M.L. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996, 23:259-263.
100. Loprinzi C.L., Abu-Ghazaleh S., Sloan J.A., et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997, 15:969-973.
101. Derzko C., Elliott S., Lam W. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol 2007, 14(Suppl. 1):S20-S40.
102. Pandya K.J., Morrow G.R., Roscoe J.A., et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomized double-blind placebo-controlled trial. Lancet 2005, 366:818-824.
103. Stearns V., Johnson M.D., Rae J.M., et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003, 95:1758-1764.
104. Biglia N., Torta R., Roagna R., et al. Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas 2005, 52:78-85.
105. Goldberg R.M., Loprinzi C.L., O'Fallan J.R., et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994, 12:155-178.
106. Loprinzi C.L., Michalak J.C., Quella S.K., et al. Megestrol acetate for the prevention of hot flashes. N Eng J Med 1994, 331:347-352.
107. Loprinzi C.L., Barton D.L., Sloan J.A., et al. Mayo Clinic and North Central Cancer Treatment Group hot flash studies: a 20-year experience. Menopause 2008, 15:655-669.
108. Jin Y., Desta Z., Stearns V., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005, 97:30-39.
109. Staropoli C.A., Flaws J.A., Bush T.L., Moulton A.W. Predictors of menopausal hot flashes. J Womens Health 1998, 7:1149-1155.
110. Harris P.F., Remington P.L., Trentham-Dietz A., Allen C.I., Newcomb P,A. Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage 2002, 23:501-509.
111. Deng G., Vickers A.J., Yeung S., et al. Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. J Clin Oncol 2007, 25:5584-5590.
112. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol 2005, 23:1636-1643.
113. Moy B., Elliott C.R., Chapman J.-A.W., et al. NCIC CTG MA.27: menopausal symptoms of ethnic minority women. Breast Cancer Res Treat 2006, 100(1):S144. [abstract 3059].
114. Goss P.E. Extending the benefits of adjuvant therapy in early HR+ breast cancer. Breast Cancer Res Treat 2008, 112(Suppl 1):45-52.
115. Mamounas E.P., Lembersky B., Jeong J.H., et al. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 2006, 7:416-421.
116. De Boer R., Burris H., Monnier A., et al. Oon behalf of the H2H trial steering committee The Head to Head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. J Clin Oncol 2006, 24(18S):582s. [abstract 10672].